Understanding genetic risks for thyroid cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research focuses on identifying hereditary risk factors for thyroid cancer by studying families with a history of the disease. Participants, including children and adults with known or suspected thyroid cancer or nodules, will provide family and medical history information along with blood or saliva samples for genetic analysis. The study aims to perform DNA sequencing to uncover genetic alterations that may contribute to thyroid cancer development. By understanding these genetic factors, researchers hope to improve risk assessment and management for affected families.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Individual pediatric patient with current or previous known or suspected thyroid cancer or nodule(s).
* Individual adult patient with current or previous known or suspected thyroid cancer or nodule(s) if they come from a family with a high suspicion of hereditary cancer (as below).
* Individuals from families with a high suspicion of hereditary thyroid cancer:

  * Families with a current or previous diagnosis of a thyroid cancer/nodule occurring in childhood (\<18 years old).
  * Families with a high suspicion of hereditary thyroid cancer/nodules other than above to include:

    * Families with thyroid cancer in multiple individuals
    * Families with thyroid cancer and a known genetic syndrome
    * Families with thyroid cancer and a suspected genetic syndrome (e.g. multiple childhood cancers in the family, multiple primary cancers, multiple endocrinopathies, etc.)

Exclusion Criteria:

* Individuals who are unable to give informed consent.
* Individuals who are unable to complete study materials.

Where it's running

• Dana Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Junne Kamihara, MD, PhD — Dana-Farber Cancer Institute
• Study coordinator: Junne Kamihara, MD, PhD
• Email: junne_kamihara@dfci.harvard.edu
• Phone: 617.632.3044

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MRG003 added to ongoing treatment after progression in EGFR-positive advanced thyroid cancer

  In this study, researchers test whether adding MRG003 to a patient’s current thyroid cancer treatment can shrink tumors for those whose cancer initially responded but later progressed.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07874321

• Selective coverage radiotherapy vs. full coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer

  This trial tests whether covering only the tumor-affected area with radiation is as effective as full-area coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer, while aiming to reduce side effects and improve quality of life.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07777536

• Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer

  This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07753499

• WeChat-supported neck exercises after thyroidectomy

  A telehealth program using a WeChat mini program tests if guided neck exercises after thyroid surgery help early recovery and quality of life.

  Recruiting Shanghai 6th People's Hospital · Shanghai, Shanghai Municipality · NCT07707401

• Pralsetinib Drug Interaction Study in RET Fusion/MUTATION Positive Solid Tumors

  This trial tests whether pralsetinib changes how the body processes certain medicines in adults with RET fusion- or mutation-positive advanced solid tumors.

  Recruiting at 2 sites Phase 4 Rigel Pharmaceuticals · Logroño, La Rioja and 1 other locations · NCT07704658

• AI chatbot to guide thyroid cancer patients through perioperative education

  A new AI chatbot is being tested to see if it helps thyroid cancer patients better prepare for discharge, recover well, and stay engaged in their care compared with traditional education.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07634978

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.